StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
HQL$17.60-1.46%
Fair $17.60+0.0%

HQL

Abrdn Life Sciences Investors

Financial Services / Asset ManagementNYSE

$17.60

-0.26 (-1.46%)

Fairly Valued+0.0%Fair Value $17.60Fund rank 29/100 · Data gapFallback financials|
SA 29/D
F-Score: 2/9

Book/ROE base 3Y

n/d

n/d CAGR · P/B n/d

Book/ROE base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 100% · confianza 20%

Book/ROE escenarios

weak_data · book/share n/d · quality 44.0/100

Data gap 29/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 59/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

29/100

D

Piotroski

2/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

16/100

SEC 0%

Latest source: unknownPeriods: 4Warnings: 0unknown: 4
No SEC-backed annual rows; valuation uses fallback financial data. Insufficient audited annual history (<3 SEC-backed years); financial Book/ROE targets are disabled until manually verified.
Thesis & Journal · HQLLocal privado en este navegador · Abrdn Life Sciences Investors
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$535M

P/E

6.3x

↓

EV/EBITDA

N/A

•

ROE

16.7%

↑

Gross Margin

N/A

•

Debt/Equity

N/A

•
52-Week Range$18
$12$18

TradingView lightweight chart

HQL price, volumen y niveles de valoración

Último $17.60Periodo -13.1%
Fair value: $17.60

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2022–2025 · 3 años de histórico normalizado

Revenue CAGR

—

FCF CAGR

—

FCF margin

36.7%

FCF / Net income

0.37x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $86.4M · net income $85.6M · FCF $31.7M

2022-FY → 2025-FY

Gross margin

—— pts

Operating margin

—— pts

Net margin

99.1%-2.2% pts

FCF margin

36.7%— pts
MetricTTM
2025
2024
2023
2022
Income Statement
Revenue$86.4M$86.4M$86.7M$23.5M$-103.3M
Net Income$85.6M$85.6M$85.3M$22.4M$-104.6M
EPS——3.040.79-4.26
Net Margin99.1%99.1%98.4%95.0%101.3%
Balance Sheet
Current Ratio0.730.73———
Cash Flow
Free Cash Flow$31.7M$31.7M———
Returns
ROE16.7%16.7%18.6%5.6%-26.3%
Valuation
P/E6.316.314.9215.85—
P/B1.011.010.910.880.85
Growth & Yield
Revenue Growth-0.3%-0.3%268.5%122.8%—
EPS Growth——284.8%118.5%—
Dividend Yield11.4%11.4%———

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%
Reverse DCF requires positive EPS; loss-making or zero-EPS companies cannot produce a clean EPS hurdle.

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · 1Y approxreconcilia total +55.2%

Total return

+55.2%

Start / end P/E

n/dx → n/dx

EPS bridge

3.04 → n/d

Residual

+43.8%

EPS growthn/d
Multiple reratingn/d
Dividend+11.4%
Residual / FX / buybacks / cross-term+43.8%

EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.